The study is looking at a number of primary and secondary endpoints across 4 subgroups (based on antibody status). How will the authors control for multiplicity of testing and assure adequate power given the dataset they are requesting.
Not ApproveThe study is looking at a number of primary and secondary endpoints across 4 subgroups (based on antibody status). How will the authors control for multiplicity of testing and assure adequate power given the dataset they are requesting.
Not Approve